Insights

Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.

John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jia Ruan, MD, PhD, shares expert insight regarding recent and ongoing studies on treatment combinations for elderly and/or high-risk patients with mantle cell lymphoma.

At the 2024 Great Debates and Updates in Hematological Malignancies Meeting, Jia Ruan, MD, PhD, discusses the emergence of novel non-chemotherapy agents as initial therapeutic options for patients with mantle cell lymphoma, focusing on the...

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, emphasizes the importance of continuing clinical trials for patients with Hodgkin lymphoma to gather valuable treatment data.

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.

John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.

Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...